EU and US could reach trade deal this weekend - Reuters
Rodney Gonsalves, Vice President and Corporate Controller at Agilent Technologies (NYSE:A), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Gonsalves sold 1,907.603 shares of Agilent common stock on March 17, 2025, at an average price of $121.981 per share, totaling approximately $232,691. The transaction occurred with the stock trading near its 52-week low of $117.17, in a company currently valued at $34.86 billion. InvestingPro analysis indicates the stock is currently fairly valued based on its proprietary Fair Value model.
Following this transaction, Gonsalves holds 21,785.8917 shares directly. Additionally, he has indirect ownership of 40.192 shares through the Gonsalves Trust, where both Rodney and Rochelle Gonsalves serve as trustees.
This transaction is part of routine filings that executives must report, providing transparency about their dealings in company stock.
In other recent news, Agilent Technologies reported its Q1 2025 earnings, surpassing Wall Street’s expectations with an earnings per share of $1.31, exceeding the forecast of $1.27. The company’s revenue for the quarter reached $1.68 billion, slightly above the anticipated $1.67 billion. Despite a softer outlook for the second quarter, Agilent’s full-year guidance remains unchanged, anticipating around 3% organic growth. Stifel analysts maintained a Buy rating on Agilent, setting a price target of $151, emphasizing the company’s favorable market exposures and growth drivers. In the European Union, Agilent’s PD-L1 IHC 28-8 pharmDx kit gained new approvals for use in early-stage non-small cell lung cancer and advanced melanoma, expanding its indications to nine. The company continues to lead in the life sciences and diagnostics sectors, with strong growth in PFAS testing and food markets. Agilent’s management highlighted ongoing strategic initiatives aimed at margin expansion and market leadership. These developments underscore Agilent’s strategic positioning and growth prospects amid a challenging backdrop for the broader industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.